New Discussion Groups for Big, Small, Mid-Sized Pharma & Generics

Ensuring your Gross-to-Net calculations are accurate is a messy business, and now more than ever, enormous complexity exists due to a shifting payer mix stemming from healthcare reform.

At IIR’s 2nd Annual Gross-to-Net Accounting Forum, we know how important it is for you to be able to benchmark your systems and methodologies against best practices—and that the calculations are very different for large, small to mid-sized pharma, and generic companies. For that reason, we are introducing new unique tailored discussion groups specific to your company size and function where you can discuss and share challenges with like-minded peers.

Collaborate across managed markets, commercial, government programs and finance with your dedicated discussion group leaders:

• Big Pharma – Courtney Callihan, Finance Director, GlaxoSmithKline
• Small to Mid-Sized Pharma – Larry Breen, Director of Financial Planning and Analysis, Sunovion Pharmaceuticals
• Generics – Roxana Santiago, Senior Finance Manager Gross to Net, Hospira Worldwide, Inc. 

To full our full program, download the 2014 brochure.

Register today using code XP1911BLOG and receive 15% off the standard rate. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage. We look forward to seeing you June 17-18 in Philadelphia!

Best,
The GTN Team

Opt-in for updates
Follow us on Twitter
GTN LinkedIn

Download the Full Brochure For IIR's Gross-To-Net Accounting Forum

IIR’s 2nd Annual Gross-To-Net Accounting Forum for Pharmaceutical Manufacturers, taking place on June 17-18th in Philadelphia, is back by popular demand! Join branded and generic manufacturers and large, medium and small pharma to learn how to calculate liability and predict channel shifts through a collaborative GTN process.

2014 Highlights include:

• New tailored discussion groups to collaborate across Managed Markets, Commercial, Government Programs and Finance for Big, Small to Mid-Sized Pharma, and Generics
• First opportunity to get up close and personal with the AMP Final Rule at the pre-conference workshop
• Never-before-heard case studies on GTN automation and chargeback methodology, in addition to strategic forecasting panel discussions
• Quantifying approaches for the impact of Medicaid, 340B and Healthcare Reform

To full our full program, download the 2014 brochure.

Register today using code XP1911BLOG and receive 15% off the standard rate. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you June 17-18 in Philadelphia!

Best,
The Gross-to-Net Team

Opt-in for updates
Follow us on Twitter
GTN LinkedIn

Hurry! There is still time left to register for the Gross-to-Net Accounting Forum taking place next week, June 17-18.

Are you ready? We’ve got a packed agenda including in-depth coverage on Chargebacks and the Impacts of Healthcare Reform on Medicaid Liability to ensure you leave with the complete GTN perspective. You will hear directly from experts at big and small pharma, and branded and generic companies on key areas such as:

• Accruals
• Wholesaler Returns
• New Product Launches
• Managed Care
• Chargebacks
• Medicaid Liability

Register today using code XP1811BLOG and receive 15% off the standard rate!

Want to learn more? Download our brochure. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you next week!

Best,
The Pharmaceutical Accounting, Financial, & Reporting Team

Visit our homepage: http://bit.ly/10fsWay
Follow us on Twitter

TOP TEN REASONS TO ATTEND IIR'S GROSS-TO-NET ACCOUNTING FORUM

10. Take part in the excitement. The buzz for this event has been building each week, with positive feedback from our growing attendee list.

9. Ensure your revenue deductions are accurate. Novartis will show how one of the largest pharmaceutical manufacturers have streamlined and perfected its process.

8. Efficiently manage your commercial and government contracts. Two case studies will touch upon this very delicate balancing act: “Account for the Government Pricing and Contracting Impact on Gross-to-Net Calculations” and “Commercial Contracts and GTN for Managed Care.”

7. Facilitate inter-departmental collaboration. Communication is key, and this event ensures interactivity among all the attendees to bring together the different departments that are key to success.

6. Forecast for new product launches. Hear a case study on Incyte’s successful product launch from its Senior Director of Finance.

5. Be prepared for the unknown. Be able to identify and anticipate Managed Care rebates that will change moving into 2014.

4. Gross-to-Net Nirvana. Unravel the complexities of rate calculations and the role of historical data and contract terms for accurate accruing in the session "Closing the Gap between Excel and ERP."

3. Earn CPE Credits! Get up to 15 CPE credits over two days!

2. Get the full 360⁰ GTN perspective. Hear experts from big and small pharma on key areas such as: accruals, wholesaler returns, new product launches, managed care, chargebacks, and Medicaid liability.

1. Because your bottom line depends on attending. More and more of your peers are registering each week…why aren’t you?

It's not too late to register! As a reader of the healthcare insights blog, you'll receive 15% off the standard rate when using code XP1811BLOG. 

Want to learn more? Download our brochure. We look forward to seeing you June 17-18 in Chicago!

Look Who’s Attending the Gross-to-Net Forum

The Gross-to-net Accounting Forum will be here before you know it—seats are filling up rapidly!

Since its introduction, the buzz for this event has been building more and more each week, with positive feedback from our growing attendee list. Join us and the confirmed attendees from the following companies to ensure you do not miss out on learning the newest developments in the GTN process.

Acorda Therapeutics*Actient Pharmaceuticals*Afaxys, Inc*Alliance Life Sciences Consulting*AMAG Pharmaceuticals Inc*Amgen*Amneal Pharmaceuticals*APP Pharmaceuticals, LLC*ARIAD Pharmaceuticals Incorporated*Astellas Pharma US*AstraZeneca*Bayer HealthCare Pharmaceuticals*Boehringer Ingelheim Pharmaceuticals*BPI Technologies*Covidien*Daiichi Sankyo*DDN*Eli Lilly & Co*Exelixis*Faulkner Mackie & Cochran PC*Forest Laboratories Inc*Forest Pharmaceuticals Inc *GlaxoSmithKline*Grifols*IMS HEALTH*Incyte*Jazz Pharmaceuticals*King & Spalding LLP*LEO Pharma Inc*Millennium: The Takeda Oncology Company*Mylan*Neos Therapeutics*Optimer Pharma*PPS - Professional Provider Services Inc.*Purdue Pharma*Revitas*Salix Pharmaceuticals*Sanofi-Aventis*Shionogi Inc.*Sunovion Pharmaceuticals*Vertex Pharmaceuticals*Vertical / Trigen*Warner Chilcott

Any many more! To view our full program, download our brochure.

As a reader of the healthcare insights blog, you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you this June!

Best,
The GTN Team

Visit our homepage
Follow us on Twitter

Session Spotlight: Process Evaluation for Small to Mid-Sized Pharmaceutical Companies

Gross-to-Net calculations are not just for big pharma. While the larger organizations have a variety of people across several functions involved in the process, smaller companies make do with far fewer resources. In this session, leaders in smaller pharmaceutical companies address unique challenges inherent to companies their size and much more. 

Session: Process Evaluation for Small to Mid-Sized Pharmaceutical Companies

Speakers:
Paul Troiano, Senior Director, Commercial Finance, OPTIMER PHARMACEUTICALS
 Alberto Bonilla, Director, Commercial Finance, WARNER CHILCOTT

It’s not a new story that smaller pharmaceutical companies often have a more difficult time than their larger counterparts. One person might have the same function as four different people at a larger company. This session discusses some of the additional challenges such as who should be involved in estimating GTN and to what capacity, and how professionals devise estimates when the company lacks a large number of products to draw analogies from and how do they estimate returns.

Want to learn more? Download our brochure.

The Gross-to-Net Accounting Forum takes place June 17-18 in Boston, MA. As a reader of this blog you'll receive 15% off the standard rate by using code XP1811BLOG when you register. We look forward to seeing you this June!

Session Spotlight: Account for the Government Pricing and Contracting Impact on Gross-to-Net Calculations

As the largest healthcare provider to the American population, the US government has a significant impact on pharmaceutical company financials. With Medicaid expansion continuing into 2014, this impact is only going to grow. Manufacturers must calculate prices for each product, along with the reimbursement rate on each prescription. These rebates make GTN calculations a time-consuming endeavor for finance divisions, so what is the best way to proceed?

Session: Account for the Government Pricing and Contracting Impact on Gross-to-Net Calculations

Speaker: Jennifer Norton, Senior Director, Pricing & Contract Administration - Managed Markets, Vertex Pharmaceuticals , Inc.

The US Government is the largest healthcare provider to the American population and therefore has a significant impact on pharmaceutical company financials. Each day we hear of another state’s decision whether or not to expand Medicaid, as is their option. As some states decide to expand, the government’s impact on company financials will only continue to grow. Government reimbursement and rebates have a direct impact on GTN calculations. In this session, executives from Vertex Pharmaceuticals will discuss how government pricing and contracting affects GTN and the operational challenges that arise that affect that calculation.

Want to learn more? Download our brochure.

The Gross-to-Net Accounting Forum takes place June 17-18 in Boston, MA. As a reader of this blog you'll receive 15% off the standard rate by using code XP1811BLOG when you register. We look forward to seeing you this June!

The GTN Webinar is tomorrow, reserve your seat today!

The Gross-to-Net Forecasting & Reporting Impacts: New Product Launch/Acquisition, LOE and Returns Reserve Methodology is happening tomorrow, but you can still register today!

This webinar will be lead by David Levi from Bristol-Myers Squibb and Jennifer Sharpe from Professional Provider Services, Inc. Together, David and Jen will pool their personal experience, network of clients and industry colleagues to provide the audience with best practices and an interactive discussion on these key product milestones.

Space is limited, reserve your seat today.

DATE: May 8, 2013
TIME: 11:00am-12pm EST
SPEAKERS: David Levi Executive Director Finance US Controller & Global Commercial Controls, Bristol-Myers Squibb

Jennifer Sharpe Director of Managed Markets Projects & Business Development, Professional Provider Services, Inc.

COST: Complimentary

To learn more about the Gross-To-Net Accounting Forum, download our brochure.

As a reader of Healthcare Insights blog, you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

Gross-to-Net Forum — Full Speed Ahead

The Gross-to-Net Accounting Forum is less than 2 months away, and I couldn’t be more excited about the enthusiasm and excitement surrounding the event. Demand for this event is extremely high indicating how timely and imperative GTN content is and how crucial it is to your business.

We’ve got a packed agenda including in-depth coverage on Chargebacks and the Impacts of Healthcare Reform on Medicaid Liability to ensure you leave with the complete GTN perspective. You will hear directly from experts at big and small pharma, and branded and generic companies on key areas such as:

• Accruals
• Wholesaler Returns
• New Product Launches
• Managed Care
• Chargebacks
• Medicaid Liability

To find out more about the 2013 program, download the agenda.

As a reader of the healthcare insights blog, you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you this June!

Best,
The Pharmaceutical Accounting, Financial, & Reporting Team

Visit our homepage: http://bit.ly/18b11JF
Follow us on Twitter

P.S. Our webinar is next week, don’t forget to register!

The Gross-to-Net Account forum will be here before you know it—seats are already filling up!

Since its introduction, the buzz for this event has been building more and more each week, with positive feedback from our growing attendee list.

Join us to ensure you do not miss out on learning the newest developments in the GTN process. Plus, this is a great opportunity to meet our distinguished 2013 GTN speaker faculty, and receive one-to-one help to develop operational strategies that will minimize the variances impacting your bottom line, including:

· Commercial Contracts and Managed Care - Tara Brodo, Director, Contract and Analytics, DAIICHI SANKYO

· Case Study: Budgeting, Planning, Accounting & Financial Controls Impact of Government - Brett Nussbaum, Head, Revenue Deductions, NOVARTIS

· Impact of Government Pricing and Contracting - Jennifer Norton Sr. Pricing & Contract Administration, VERTEX PHARMACEUTICALS

· Small/Mid-Sized Pharma Perspective for GTN Calculations - Paul Troiano Sr. Director, Commercial Finance, OPTIMER PHARMACEUTICALS

To find out more about the 2013 program, download the agenda.

 As a reader of this blog, you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you this June!

Best,
The Gross-to-Net Accounting Forum Team

P.S. Don’t forget to register for our Webinar taking place: May 8th 11:00-12:00 PM EST. Space is limited. Reserve your Webinar seat now!

Learn How Government Drug Pricing Affects Your Bottom Line

Pharmaceutical financial executives have a lot on their plates. You are responsible for understanding how each expense impacts your company’s bottom line. With government rebate programs affecting those bottom lines, it is imperative that you understand how major events like Healthcare Reform can be quantified and how those quantifications have financial and operational impacts on your company.

At the 17th Annual Medicaid Drug Rebate Program Summit, September 10-12, 2012 in Chicago, IL, you will learn from industry experts how to apply your knowledge - and theirs – of the rebate area to improve your financial forecasts.

In our exclusive track, “Financial Implications of MDRP and Other Government Pricing Programs,” you will hear from leading industry experts on these topics:

• - Understand and Predict the Financial Opportunities and Impacts of Medicaid Compliance
• - Understand the Impact of Actual Acquisition Cost on Contracting and Brand Reimbursement
• - Learn Best Practices for Handling Data Growth
• - Develop Best Practices for Recalculations

For more information on the sessions in this track and the rest of the agenda, download the brochure. 


As a reader of this blog, you'll receive an exclusive discount of 25% off of the standard price when you register to join us this September 10-12, 2012 in Chicago, IL. Simply use priority code XP1758BLOG. Do you have any questions about the event? Feel free to contact Jennifer Pereira.